Cancer statistics. CA Cancer J Clin 2008;58:71-96.
Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long-term survivors. Head Neck 2002;24(8):737-47.
A prospective study on quality of life of patients with cancer of the oral cavity or oropharynx treated with surgery with or without radiotherapy. Oral Oncol 1999;35(1):27-32.
Health-related quality of life in long-term head and neck cancer survivors: A comparison with general population norms. Br J Cancer 2001;84(2):149-56.
Health-related quality of life 3 years after diagnosis of head and neck cancer a longitudinal study. Head Neck 2001;23(2):113-25.
Radiation-induced xerostomia: Pathophysiology, Prevention and Treatment Clinical. Oncology 2009;21:737-44.
A review of saliva: Normal composition, flow and function. J Prosthet Dent 2001;85(2): 162-69.
Radiation induced cell loss in rat submandibular gland and its relation to gland function. Int J Radiat Biol 2000;76(3):419-29.
Changes in serum and salivary amylase during radiotherapy for head and neck cancer: A comparison of conventionally fractionated radiotherapy with CHART. Radiother Oncol 1992;24(1):27-31.
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 2001;49: 907-16.
Dose-volume modelling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:1055-69.
Individual radiation response of parotid glands investigated by dynamic 11C-methionine PET. Radiother Oncol 2006;78:262-69.
Fractionated irradiation and early changes in noradrenaline induced potassium efflux (86Rb+) in rat parotid gland. Acta Oncol 1992;31:359-64.
Effects of continuous hyperfractionated accelerated and conventionally fractionated radiotherapy on the parotid and submandibular salivary glands of rhesus monkeys. Radiother Oncol 1995;34:39-46.
The early changes in salivary gland function during and after radiotherapy for head and neck cancer. Radiother Oncol 1994;30:26-32.
Assessment of salivary gland dysfunction following chemoradiotherapy using quantitative salivary gland scintigraphy. Int J Radiat Oncol Biol Phys 1999;45(2):379-84.
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78.
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18(19):3339-45.
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebocontrolled phase III study. Int J Radiat Oncol Biol Phys 2006;64(3):684-91.
American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27(1):127-45.
Phase III quality-of-life study results: Impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer RTOG 97-09. Int J Radiat Oncol Biol Phys 2003;56(3):832-36.
A phase III placebocontrolled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;54(1):9-13.
Parotid gland sparing in patients undergoing bilateral head and neck irradiation: Techniques and early results. Int J Radiat Oncol Biol Phys 1996;36(2):469-80.
Xerostomia and quality of life after intensity-modulated radiotherapy vs conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981-91.
Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873-79.
First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). Proc Am Soc Clin Oncol 2009;27(suppl 18): abstr LBA6006.
Radiotherapy dose– volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 2010;76(3),S58-63.
Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol 2010;11:85-91.
Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 2000;46:7-11.
Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 2006; 78:270-75.
Dose-effect relationships for the submandibular glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:373-82.
A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction. Spec Care Dentist 1992;12(1):21-23.
Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329(6):390-95.
A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993; 11(6):1124-31.
Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjogren's syndrome. Adv Exp Med Biol 2002;506(Pt B):1107-16.
Acupuncture treatment of patients with radiation induced xerostomia. Eur J Cancer B Oral Oncol 1996;32B(3):182-90.
Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 2000;6(1):15-24.
A phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(2):472-80.
The use of gene transfer for the protection and repair of salivary glands. Oral Dis 2002;8(4):183-91.